Physical health monitoring of patients with schizophrenia.

OBJECTIVE Schizophrenia is associated with several chronic physical illnesses and a shorter life expectancy, compared with life expectancy in the general population. One approach to improving the health of patients with schizophrenia is to improve the monitoring of physical health that occurs in psychiatric settings. The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings. METHOD A consensus meeting including psychiatric and other medical experts assembled on October 17-18, 2002, to evaluate the existing literature and to develop recommendations for physical health monitoring of patients with schizophrenia. Conference participants reviewed the literature in the following areas: 1) weight gain and obesity; 2) diabetes; 3) hyperlipidemia; 4) prolongation of the QT interval on the ECG; 5) prolactin elevation and related sexual side effects; 6) extrapyramidal side effects, akathisia, and tardive dyskinesia; 7) cataracts; and 8) myocarditis. Experts for each topic area formulated monitoring recommendations that were discussed by all of the participants until a consensus was reached. RESULTS Consensus recommendations included regular monitoring of body mass index, plasma glucose level, lipid profiles, and signs of prolactin elevation or sexual dysfunction. Information from monitoring should guide the selection of antipsychotic agents. Specific recommendations were made for cardiac monitoring of patients who receive medications associated with QT interval prolongation, including thioridazine, mesoridazine, and ziprasidone, and for monitoring for signs of myocarditis in patients treated with clozapine. Patients who receive both first- and second-generation antipsychotic medications should be examined for extrapyramidal symptoms and tardive dyskinesia. Patients with schizophrenia should receive regular visual examinations. CONCLUSIONS The conference participants recommended that mental health care providers perform physical health monitoring that typically occurs in primary care settings for their patients who do not receive physical health monitoring in those settings. This change in usual practice is recommended on the basis of the conference participants' belief that this additional monitoring will result in the earlier detection of common, serious risk factors that could, without detection and intervention, contribute to impaired health of patients with schizophrenia.

[1]  J. Ananth,et al.  Atypical Antipsychotic Drug Use and Diabetes , 2002, Psychotherapy and Psychosomatics.

[2]  J. Avorn,et al.  Clozapine Use and Risk of Diabetes Mellitus , 2002, Journal of clinical psychopharmacology.

[3]  David C. Atkins,et al.  Screening and treating adults for lipid disorders. , 2001, American journal of preventive medicine.

[4]  M. F. Denisov Re: Prolactin levels and adverse events in patients treated with risperidone. , 2002, Journal of clinical psychopharmacology.

[5]  S. Kennedy,et al.  Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities , 2001, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[6]  Jonathan M. Meyer A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. , 2002, The Journal of clinical psychiatry.

[7]  W. Glazer,et al.  Neuroleptic-induced hyperprolactinemia , 1999, Schizophrenia Research.

[8]  C. Tamminga,et al.  Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. , 1997, The American journal of psychiatry.

[9]  A. Breier,et al.  The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. , 2000, Clinical therapeutics.

[10]  Jonathan M. Meyer Novel antipsychotics and severe hyperlipidemia. , 2001 .

[11]  S. Marder,et al.  Novel antipsychotics: comparison of weight gain liabilities. , 1999, The Journal of clinical psychiatry.

[12]  D. Goff,et al.  Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. , 2000, The American journal of psychiatry.

[13]  H. Meltzer,et al.  Neuroleptic-induced prolactin level elevation and breast cancer: an emerging clinical issue. , 1978, Archives of general psychiatry.

[14]  R. Buchanan,et al.  A program for treating olanzapine-related weight gain. , 2001, Psychiatric services.

[15]  G. Tollefson,et al.  Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. , 2001, The Journal of clinical psychiatry.

[16]  D. Celermajer,et al.  Myocarditis and cardiomyopathy associated with clozapine , 1999, The Lancet.

[17]  J. Avorn,et al.  Dopamine antagonists and the development of breast cancer. , 2002, Archives of general psychiatry.

[18]  N. Ben-Jonathan,et al.  Dopamine as a prolactin (PRL) inhibitor. , 2001, Endocrine reviews.

[19]  J. Lieberman,et al.  Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.

[20]  J. Lieberman,et al.  Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. , 2003, The American journal of psychiatry.

[21]  Alexander L. Miller,et al.  The Mount Sinai conference on the pharmacotherapy of schizophrenia. , 2002, Schizophrenia bulletin.

[22]  T. van Putten Why do schizophrenic patients refuse to take their drugs? , 1974, Archives of general psychiatry.

[23]  D. Allison,et al.  Changes in body mass index for individuals with and without schizophrenia, 1987–1996 , 2002, Schizophrenia Research.

[24]  S. Marder,et al.  The effects of novel antipsychotics on glucose and lipid levels. , 2002, The Journal of clinical psychiatry.

[25]  R. Murray,et al.  The Effects of Antipsychotic-Induced Hyperprolactinaemia on the Hypothalamic-Pituitary-Gonadal Axis , 2002, Journal of clinical psychopharmacology.

[26]  Robert Ross,et al.  Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. , 2002, Archives of internal medicine.

[27]  A. Trontell,et al.  Myocarditis and cardiomyopathy associated with clozapine use in the United States. , 2001, The New England journal of medicine.

[28]  P. Mortensen Neuroleptic treatment and other factors modifying cancer risk in schizophrenic patients , 1987, Acta psychiatrica Scandinavica.

[29]  L. Arvanitis,et al.  Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo , 1997, Biological Psychiatry.

[30]  M. Heo,et al.  The distribution of body mass index among individuals with and without schizophrenia. , 1999, The Journal of clinical psychiatry.

[31]  R. Dufresne,et al.  Olanzapine increases weight and serum triglyceride levels. , 1999, The Journal of clinical psychiatry.

[32]  A H Glassman,et al.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. , 2001, The American journal of psychiatry.

[33]  David M Nathan,et al.  Tests of Glycemia for the Diagnosis of Type 2 Diabetes Mellitus , 2002, Annals of Internal Medicine.

[34]  R. Tamura,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.

[35]  K. Brismar,et al.  Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. , 1999, The Journal of clinical psychiatry.

[36]  G. L. Noel,et al.  Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. , 1977, The New England journal of medicine.

[37]  G. L’italien,et al.  An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. , 2002, Archives of general psychiatry.

[38]  J. Bustillo,et al.  Differential effect of clozapine on weight: a controlled study. , 1996, The American journal of psychiatry.

[39]  P. Goodnick Ziprasidone: profile on safety , 2001, Expert opinion on pharmacotherapy.

[40]  R. Dufresne,et al.  Serum triglyceride levels in patients treated with clozapine. , 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[41]  S. Kasper,et al.  Review of quetiapine and its clinical applications in schizophrenia , 2000, Expert opinion on pharmacotherapy.

[42]  D. Menkes,et al.  Cardiotoxicity and Prescription of Thioridazine in New Zealand , 2002, The Australian and New Zealand journal of psychiatry.

[43]  H. Hein,et al.  Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. , 1998, Circulation.

[44]  K. Brismar,et al.  Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. , 2000, The Journal of clinical psychiatry.

[45]  Julie Kreyenbuhl,et al.  Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study , 2002, BMJ : British Medical Journal.

[46]  P. Doelken,et al.  Droperidol Causes a Dose‐dependent Prolongation of the QT Interval , 1994, Anesthesia and analgesia.

[47]  F. Arellano,et al.  Are Schizophrenia or Antipsychotic Drugs a Risk Factor for Cataracts? , 2000, Epidemiology.

[48]  D. Allison,et al.  Antipsychotic-induced weight gain: a review of the literature. , 2001, The Journal of clinical psychiatry.

[49]  W. Gsell,et al.  Neuroleptic-Induced Hyperprolactinaemia ??? a Case Series , 2006 .

[50]  E. Eşel,et al.  Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients , 2001, Psychoneuroendocrinology.

[51]  D. Redelmeier,et al.  The treatment of unrelated disorders in patients with chronic medical diseases. , 1998, The New England journal of medicine.

[52]  L. Dixon,et al.  Prevalence and correlates of diabetes in national schizophrenia samples. , 2000, Schizophrenia bulletin.

[53]  Claude Bouchard,et al.  Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary , 1998 .

[54]  R. Aquila Management of weight gain in patients with schizophrenia. , 2002, The Journal of clinical psychiatry.

[55]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[56]  J. Lieberman,et al.  Tardive dyskinesia: prevalence, incidence, and risk factors. , 1988, Journal of clinical psychopharmacology.

[57]  R. Bland,et al.  Mortality in a Cohort of Patients with Schizophrenia: A Record Linkage Study* , 1991, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[58]  Abraham Weizman,et al.  Diminished Suicidal and Aggressive Behavior, High Plasma Norepinephrine Levels, and Serum Triglyceride Levels in Chronic Neuroleptic‐Resistant Schizophrenic Patients Maintained on Clozapine , 1998, Clinical neuropharmacology.

[59]  U. Wesselmann,et al.  Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. , 1996, Neuropsychobiology.

[60]  J. Lieberman,et al.  Prospective study of tardive dyskinesia incidence in the elderly. , 1991, JAMA.

[61]  R. Conley,et al.  A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. , 2001, The American journal of psychiatry.

[62]  W. Kannel,et al.  Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. , 2020, Annals of internal medicine.

[63]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[64]  S. Kapur,et al.  Elevation of prolactin levels by atypical antipsychotics. , 2002, The American journal of psychiatry.

[65]  G. Remington,et al.  A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. , 2001, The American journal of psychiatry.

[66]  Robert Rosenheck,et al.  Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. , 2002, The American journal of psychiatry.

[67]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[68]  J. Lieberman,et al.  Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. , 2002, The American journal of psychiatry.